Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials;Vergleichende Wirksamkeit und Sicherheit von Baricitinib 2 mg und 4 mg bei Patienten mit aktiver rheumatoider Arthritis: Eine Bayes-Netzwerkmetaanalyse randomisierter, kontrollierter Studien

Zeitschrift fur Rheumatologie

Volumn 77, Issue 4, 2018, Pages 335-342

  Lee, Y H ^a   Bae, S C ^b  

^a College of Medicine   (South Korea)

^b Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

Baricitinib; Efficacy; Network meta analysis; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; BARICITINIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; SULFONAMIDE;

ADVERSE EVENT; ARTICLE; COCHRANE LIBRARY; CONTROLLED STUDY; DATA EXTRACTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; BAYES THEOREM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; BAYES THEOREM; HUMANS; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 85009732679     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-016-0254-4     Document Type: Article

References (28)

1. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. doi:10.1016/s0140-6736(16)30173-8
2. Ghoreschi K, Laurence A, O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273–287. doi:10.1111/j.1600-065X.2008.00754.x
3. Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282:20059–20063
4. Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y (2013) The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 73(12):2192–2198. doi:10.1136/annrheumdis-2013-203756
5. Norman P (2014) Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs 23:1067–1077
6. Roskoski R Jr. (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784–803. doi:10.1016/j.phrs.2016.07.038
7. Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 54:1354–1361
8. Ghoreschi K, Laurence A, O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273–287
9. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243–1252. doi:10.1056/NEJMoa1507247
10. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74:333–340. doi:10.1136/annrheumdis-2014-206478
11. Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W (2016) Efficacy and safety of baricitinib in japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 43:504–511. doi:10.3899/jrheum.150613
12. Fleischmann R, Takeuchi T, Schlichting DE, Macias WL, Rooney T, Gurbuz S, Stoykov I, Beattie SD, Kuo W‑L, Schiff M (2015) Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): phase 3 trial results. In: Arthritis & Rheumatology. Wiley-Blackwell, Hoboken NJ, pp 07030–05774
13. Taylor PC, Keystone EC, Van Der Heijde D, Tanaka Y, Ishii T, Emoto K, Yang L, Arora V, Gaich CL, Rooney T (2015) Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy: results of a phase 3 study. In: Arthritis & Rheumatology. Wiley-Blackwell, Hoboken NJ, pp 07030–05774
14. Dougados M, van der Heijde D, Chen Y‑C, Greenwald M, Drescher E, Liu J, Beattie S, de la Torre I, Rooney T, Schlichting D (2015) LB0001 Baricitinib, and oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in patients with Active Rheumatoid Arthritis (RA) and an inadequate response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. Ann Rheum Dis 74:79–79
15. Greenwald M, Fidelus-Gort R, Levy R, Liang J, Vaddi K, Williams WV, Newton R (2010) A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis. Arthritis Rheum 62:2172
16. Kubo S, Nakayamada S, Tanaka Y (2016) Baricitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 12:911–919
17. Catalá-López F, Tobías A, Cameron C, Moher D, Hutton B (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34:1489–1496
18. Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897
19. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35:498–502
20. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Care Res 59:1371–1377
21. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
22. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses – an overview and application of NetMetaXL. Syst Rev 3:110
23. Salanti G, Ades A, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171
24. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades A (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak 33:641–656
25. Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98–110
26. Valkenhoef G, Lu G, Brock B, Hillege H, Ades A, Welton NJ (2012) Automating network meta-analysis. Res Synth Methods 3:285–299
27. Herman S, Zurgil N, Deutsch M (2005) Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 54:273–280
28. Zamora NVJT, Lopez-Olivo MA, Christensen R, Suarez-Almazor ME (2016) SAT0177 Baricitinib for rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 75:731.3